Revealing tumor immunity after hematopoietic stem cell transplantation.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19584145.
- Also identified by DOI 10.1158/1078-0432.CCR-09-0873.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Allogeneic hematopoietic stem cell transplantation is currently the most effective method for inducing tumor immunity. However, the diversity of target antigens recognized by donor T cells has not been established. New studies show that tumor-reactive T cells are directed against diverse tumor-specific targets as well as minor histocompatibility antigens.
Medical subject headings
- Hematopoietic Stem Cell Transplantation
- Leukemia, Lymphocytic, Chronic, B-Cell
- T-Lymphocytes